Price alert —
Sign in to get a one-time email the moment QGEN crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · QGEN
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.5B | $0.1B | $0.1B | $0.1B | 13.8% | 23.7% |
| 2025-12-31 | $0.5B | $0.1B | $0.1B | $0.1B | 20.0% | 22.6% |
| 2025-09-30 | $0.5B | $0.1B | $0.1B | $0.1B | 24.4% | 25.8% |
| 2025-06-30 | $0.5B | $0.1B | $0.1B | $0.1B | 18.0% | 25.5% |
| 2025-03-31 | $0.5B | $0.1B | $0.1B | $0.1B | 18.8% | 25.9% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare QGEN vs peers
Line QGEN up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with QGEN
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 0 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
No earnings history available.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| QGEN ★ | $8B | 21.0 | 15.7 | 4.0 | 13.1 | 2.5 | 66.1% | 1.8% | -23.8% | 2.81% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 28.85%
| Holder | Shares | % out |
|---|---|---|
| Wellington Management Group, LLP | 14,364,303 | 6.97% |
| Price (T.Rowe) Associates Inc | 8,429,334 | 4.09% |
| Vanguard Capital Management LLC | 6,106,275 | 2.96% |
| Deutsche Bank AG | 5,601,957 | 2.72% |
| Blackrock Inc. | 5,250,461 | 2.55% |
| Amundi | 4,757,681 | 2.31% |
| Morgan Stanley | 4,190,913 | 2.03% |
| Earnest Partners LLC | 3,868,489 | 1.88% |
| Boston Partners | 3,625,691 | 1.76% |
| Bank of America Corporation | 3,246,973 | 1.58% |
Insider activity · 90d
No insider trades for QGEN in last 90d.
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
About QGEN
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits …
Options picks · QGEN
ITM + OTM ideas from the latest scanLoading…
Congress trades · QGEN
STOCK Act disclosuresLoading…
SEC filings & insiders · QGEN
EDGAR · liveLoading…
Holders · QGEN
Institutions & insider activityLoading…